Spondyloarthritis & psoriatic arthritis
Association of MICA and NKG2D genetic variants with disease susceptibility and outcome of anti-TNF therapy in patients with axial spondyloarthritis
Authors' conclusion
These results suggest that MICA and NKG2D gene polymorphisms may be biomarkers associated with disease susceptibility and clinical outcomes after anti-TNF therapy in axSpA patients and imply a rather less favourable effect of the MICA A and NKG2D G genetic variants.
Study context
- Population
- Axial spondyloarthritis (axSpA) patients treated with TNF inhibitors and healthy controls
- Participants
- 163 vs 234
- Comparison
- axSpA patients treated with TNF inhibitors vs healthy controls; genotypes of MICA rs1051792 and NKG2D rs1154831, rs1049174, rs2255336
- axSpAn = 163
- Healthy controlsn = 234reference
- Outcome
- Associations of MICA and NKG2D SNPs with disease susceptibility and clinical parameters during anti-TNF therapy
Methodological detailscase-control, real-time PCR genotyping
- Case-control
- Real-time PCR genotyping
Main finding
As reported in the abstract
Disease susceptibility: MICA rs1051792 A allele
- axSpA vs Healthy controls: P < 0.0001
Observational data: associations, not effects.
Further findings
BASDAI by MICA rs1051792 genotype (AA vs G carriers) · 3 and 6 months of treatment
- AA genotype greater BASDAI than G carriers at 3 months
- P = 4×10-4
- AA genotype greater BASDAI than G carriers at 6 months
- P = 0.032
Anti-TNF response by MICA AA homozygosity · 3 months
- MICA AA more often in non-/moderate responders than good responders
- P = 1×10-4
NKG2D rs1154831 CC genotype: BASDAI and outcome · 6 months of treatment
- CC genotype lower BASDAI
- P = 0.035
- CC genotype more common among good outcome
- P = 0.004
Original publication
Association of MICA and NKG2D genetic variants with disease susceptibility and outcome of anti-TNF therapy in patients with axial spondyloarthritis. Clin Exp Rheumatol. Published 20 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →